Friday, June 10, 2022

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), The Coca-Cola Company (KO), and Thermo Fisher Scientific Inc. (TMO). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Exxon Mobil shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the past year (+71.4% vs. +55.9%). The company’s bellwether status and an optimal integrated capital structure that has historically produced industry-leading returns make it a relatively lower-risk energy sector play. The company made three oil discoveries in the Stabroek Block, which will increase its recoverable resources estimates to 11 billion oil-equivalent barrels. It also has a strong presence in the prolific Permian Basin, where it continues to lower its fracking & drilling costs.

To capitalize on mounting demand for clean energy, ExxonMobil is making efforts to create more efficient fuels while reducing emissions. Notably, it has significantly lower debt exposure than other integrated majors. ExxonMobil has increased its stock repurchase program from $10 billion to $30 billion. The energy giant has planned to execute the repurchases through next year.

(You can read the full research report Exxom Mobil here >>>)

Coca-Cola shares have outperformed the Beverages - Soft drinks industry over the past year (+14.0% vs. +8.2%). The company benefited from the strategic transformation and ongoing recovery around the world. Strength across the majority of the markets, investments in the marketplace, recovery in certain markets as well as the cycling of last year’s pandemic-led impacts aided volumes. The company retained its upbeat 2022 view. It is poised to gain from innovations and accelerating digital investments.

However, pressures from higher supply chain costs, including transportation and input costs remain. Higher marketing spending are also concerning. Also, the unfavorable currency is expected to hurt the top and bottom lines in the second quarter and 2022.

(You can read the full research report Coca-Cola here >>>)

Thermo Fisher shares have outperformed the Medical - Instruments industry over the past year (+16.4% vs. -21.1%). The company’s robust year-over-year revenue growth in the Analytical Instruments and the Laboratory Products and Biopharma Services segments appears promising. The company’s strategic acquisitions of PPD, Inc. and PeproTech raise investors’ confidence. Thermo Fisher’s accelerated investments to expand bioproduction capacity also buoy optimism. The upbeat guidance for 2022 is indicative that this growth momentum will continue.

However, the year-over-year decline in revenues in the Specialty Diagnostics segment is disappointing. The contraction of both margins does not bode well either.

(You can read the full research report Thermo Fisher here >>>)

Other noteworthy reports we are featuring today include PepsiCo, Inc. (PEP), The Progressive Corporation (PGR), and Dominion Energy, Inc. (D).

Sheraz Mian
 
Director of Research

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>